-
1
-
-
73349102140
-
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
-
Mojtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009;20:851-855.
-
(2009)
Anticancer Drugs
, vol.20
, pp. 851-855
-
-
Mojtahedi, H.1
Essapen, S.2
-
2
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. The New England Journal of Medicine. 2004;350:2129-2139.
-
(2004)
The New England Journal of Medicine
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
3
-
-
35548962203
-
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
-
Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science. 2007;98:1817-1824.
-
(2007)
Cancer Science
, vol.98
, pp. 1817-1824
-
-
Mitsudomi, T.1
Yatabe, Y.2
-
4
-
-
67650378948
-
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations
-
Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clinical Cancer Research. 2009;15:4493-4498.
-
(2009)
Clinical Cancer Research
, vol.15
, pp. 4493-4498
-
-
Morita, S.1
Okamoto, I.2
Kobayashi, K.3
Yamazaki, K.4
Asahina, H.5
Inoue, A.6
Hagiwara, K.7
Sunaga, N.8
Yanagitani, N.9
Hida, T.10
Yoshida, K.11
Hirashima, T.12
Yasumoto, K.13
Sugio, K.14
Mitsudomi, T.15
Fukuoka, M.16
-
5
-
-
84862294110
-
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
-
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemotherapy and Pharmacology. 2012;69:1289-1299.
-
(2012)
Cancer Chemotherapy and Pharmacology
, vol.69
, pp. 1289-1299
-
-
Ludovini, V.1
Bianconi, F.2
Pistola, L.3
Pistola, V.4
Chiari, R.5
Colella, R.6
Bellezza, G.7
Tofanetti, F.R.8
Siggillino, A.9
Baldelli, E.10
Flacco, A.11
Giuffrida, D.12
Sidoni, A.13
Crinò, L.14
-
6
-
-
84867885308
-
Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature
-
Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature. Oral Oncology. 2012;48:1085-1089.
-
(2012)
Oral Oncology
, vol.48
, pp. 1085-1089
-
-
Rabinowits, G.1
Haddad, R.I.2
-
7
-
-
0037431759
-
Severe acute interstitial pneumonia and gefitinib
-
Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
-
(2003)
Lancet
, vol.361
, pp. 137-139
-
-
Inoue, A.1
Saijo, Y.2
Maemondo, M.3
Gomi, K.4
Tokue, Y.5
Kimura, Y.6
Ebina, M.7
Kikuchi, T.8
Moriya, T.9
Nukiwa, T.10
-
8
-
-
84876243498
-
The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases
-
Usui K, Ushijima T, Tanaka Y, Tanai C, Noda H, Abe N, Horiuchi H, Ishihara T. The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulmonary Medicine. 2011;2011:290132.
-
(2011)
Pulmonary Medicine
, vol.2011
, pp. 290132
-
-
Usui, K.1
Ushijima, T.2
Tanaka, Y.3
Tanai, C.4
Noda, H.5
Abe, N.6
Horiuchi, H.7
Ishihara, T.8
-
9
-
-
2942550603
-
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib
-
Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93-104.
-
(2004)
Lung Cancer
, vol.45
, pp. 93-104
-
-
Takano, T.1
Ohe, Y.2
Kusumoto, M.3
Tateishi, U.4
Yamamoto, S.5
Nokihara, H.6
Yamamoto, N.7
Sekine, I.8
Kunitoh, H.9
Tamura, T.10
Kodama, T.11
Saijo, N.12
-
10
-
-
44949199171
-
-
Japan Thoracic Radiology Group
-
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American Journal of Respiratory and Critical Care Medicine. 2008;177:1348-1357.
-
(2008)
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American Journal of Respiratory and Critical Care Medicine.
, vol.177
, pp. 1348-1357
-
-
Kudoh, S.1
Kato, H.2
Nishiwaki, Y.3
Fukuoka, M.4
Nakata, K.5
Ichinose, Y.6
Tsuboi, M.7
Yokota, S.8
Nakagawa, K.9
Suga, M.10
Jiang, H.11
Itoh, Y.12
Armour, A.13
Watkins, C.14
Higenbottam, T.15
-
11
-
-
33745006872
-
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
-
Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. Journal of Clinical Oncology. 2006;24:2549-2556.
-
(2006)
Journal of Clinical Oncology
, vol.24
, pp. 2549-2556
-
-
Ando, M.1
Okamoto, I.2
Yamamoto, N.3
Takeda, K.4
Tamura, K.5
Seto, T.6
Ariyoshi, Y.7
Fukuoka, M.8
-
12
-
-
0037082513
-
Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia
-
Okamoto M, Kato S, Oizumi K, Kinoshita M, Inoue Y, Hoshino K, Akira S, McKenzie AN, Young HA, Hoshino T. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood. 2002;99:1289-1298.
-
(2002)
Blood
, vol.99
, pp. 1289-1298
-
-
Okamoto, M.1
Kato, S.2
Oizumi, K.3
Kinoshita, M.4
Inoue, Y.5
Hoshino, K.6
Akira, S.7
McKenzie, A.N.8
Young, H.A.9
Hoshino, T.10
-
13
-
-
84867405669
-
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
-
Kim SM., Kwon OJ., Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 2012;11:2254-2264.
-
(2012)
Molecular Cancer Therapeutics
, vol.11
, pp. 2254-2264
-
-
Kim, S.M.1
Kwon, O.J.2
Hong, Y.K.3
Kim, J.H.4
Solca, F.5
Ha, S.J.6
Soo, R.A.7
Christensen, J.G.8
Lee, J.H.9
Cho, B.C.10
-
15
-
-
84865422083
-
Interleukin-6 signaling pathway in targeted therapy for cancer
-
Guo Y, Xu F, Lu TJ, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treatment Reviews. 2012;38:904-910.
-
(2012)
Cancer Treatment Reviews
, vol.38
, pp. 904-910
-
-
Guo, Y.1
Xu, F.2
Lu, T.J.3
Duan, Z.4
Zhang, Z.5
-
16
-
-
84866431328
-
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer
-
Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research. 2012;18:4986-4996.
-
(2012)
Clinical Cancer Research
, vol.18
, pp. 4986-4996
-
-
Sen, M.1
Joyce, S.2
Panahandeh, M.3
Li, C.4
Thomas, S.M.5
Maxwell, J.6
Wang, L.7
Gooding, W.E.8
Johnson, D.E.9
Grandis, J.R.10
-
17
-
-
0142219897
-
The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression
-
Knight DA, Ernst M, Anderson GP, Moodley YP, Mutsaers SE. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression Pharmacology & Therapeutics. 2003;99:327-338.
-
(2003)
Pharmacology & Therapeutics
, vol.99
, pp. 327-338
-
-
Knight, D.A.1
Ernst, M.2
Anderson, G.P.3
Moodley, Y.P.4
Mutsaers, S.E.5
-
18
-
-
0141860791
-
Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs
-
Moodley YP, Misso NL, Scaffidi AK, Fogel-Petrovic M, McAnulty RJ, Laurent GJ, Thompson PJ, Knight DA. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. American journal of respiratory cell and molecular biology. 2003;29:490-498.
-
(2003)
American journal of respiratory cell and molecular biology
, vol.29
, pp. 490-498
-
-
Moodley, Y.P.1
Misso, N.L.2
Scaffidi, A.K.3
Fogel-Petrovic, M.4
McAnulty, R.J.5
Laurent, G.J.6
Thompson, P.J.7
Knight, D.A.8
-
19
-
-
0035283721
-
Circulating IL-6 as a predictor of radiation pneumonitis
-
Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. International Journal of Radiation Oncology, Biology, Physics. 2001;49:641-648.
-
(2001)
International Journal of Radiation Oncology, Biology, Physics
, vol.49
, pp. 641-648
-
-
Chen, Y.1
Rubin, P.2
Williams, J.3
Hernady, E.4
Smudzin, T.5
Okunieff, P.6
-
20
-
-
0028883833
-
A histologically distinctive interstitial pneumonia induced by over expression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene
-
Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, Kishimoto T. A histologically distinctive interstitial pneumonia induced by over expression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proceedings of the National Academy of Science of the United States of America. 1995;92:9570-9574.
-
(1995)
Proceedings of the National Academy of Science of the United States of America
, vol.92
, pp. 9570-9574
-
-
Yoshida, M.1
Sakuma, J.2
Hayashi, S.3
Abe, K.4
Saito, I.5
Harada, S.6
Sakatani, M.7
Yamamoto, S.8
Matsumoto, N.9
Kaneda, Y.10
Kishimoto, T.11
-
21
-
-
69149098253
-
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship
-
Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship. Annals of the New York Academy of Sciences. 2009;1171:59-76.
-
(2009)
Annals of the New York Academy of Sciences
, vol.1171
, pp. 59-76
-
-
Aggarwal, B.B.1
Kunnumakkara, A.B.2
Harikumar, K.B.3
Gupta, S.R.4
Tharakan, S.T.5
Koca, C.6
Dey, S.7
Sung, B.8
-
22
-
-
0038036872
-
Constitutive activation of nuclear factor κB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer
-
Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor κB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Research. 2003;63:2206-2215.
-
(2003)
Cancer Research
, vol.63
, pp. 2206-2215
-
-
Zerbini, L.F.1
Wang, Y.2
Cho, J.Y.3
Libermann, T.A.4
-
23
-
-
80052520333
-
Interstitial lung disease induced by gefinitib and tolllike receptor ligands is mediated by Fra-1
-
Takada Y, Gresh L, Bozec A, Ikeda E, Kamiya K, Watanabe M, Kobayashi K, Asano K, Toyama Y, Wagner EF, Matsuo K. Interstitial lung disease induced by gefinitib and tolllike receptor ligands is mediated by Fra-1. Oncogene. 2011;30:3821-3832.
-
(2011)
Oncogene
, vol.30
, pp. 3821-3832
-
-
Takada, Y.1
Gresh, L.2
Bozec, A.3
Ikeda, E.4
Kamiya, K.5
Watanabe, M.6
Kobayashi, K.7
Asano, K.8
Toyama, Y.9
Wagner, E.F.10
Matsuo, K.11
-
24
-
-
77956635499
-
HCMV-Encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis
-
Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, Lira SA, Söderberg-Nauclér C, Smit MJ. HCMV-Encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Science Signaling. 2010;3:ra58.
-
(2010)
Science Signaling
, vol.3
-
-
Slinger, E.1
Maussang, D.2
Schreiber, A.3
Siderius, M.4
Rahbar, A.5
Fraile-Ramos, A.6
Lira, S.A.7
Söderberg-Nauclér, C.8
Smit, M.J.9
-
25
-
-
77957273623
-
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
-
Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Science of the United States of America. 2010;107:15535-15540.
-
(2010)
Proceedings of the National Academy of Science of the United States of America
, vol.107
, pp. 15535-15540
-
-
Yao, Z.1
Fenoglio, S.2
Gao, D.C.3
Camiolo, M.4
Stiles, B.5
Lindsted, T.6
Schlederer, M.7
Johns, C.8
Altorki, N.9
Mittal, V.10
Kenner, L.11
Sordella, R.12
-
26
-
-
80655139064
-
Suppression of expression of heat shock protein 70 by gefitinib and Its contribution to pulmonary fibrosis
-
Namba T, Tanaka KI, Hoshino T, Azuma A, Mizushima T. Suppression of expression of heat shock protein 70 by gefitinib and Its contribution to pulmonary fibrosis. PLoS One. 2011;6:e27296.
-
(2011)
PLoS One
, vol.6
-
-
Namba, T.1
Tanaka, K.I.2
Hoshino, T.3
Azuma, A.4
Mizushima, T.5
-
27
-
-
84857881755
-
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3
-
MacKinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine. 2012;185:537-546.
-
(2012)
American journal of respiratory and critical care medicine
, vol.185
, pp. 537-546
-
-
MacKinnon, A.C.1
Gibbons, M.A.2
Farnworth, S.L.3
Leffler, H.4
Nilsson, U.J.5
Delaine, T.6
Simpson, A.J.7
Forbes, S.J.8
Hirani, N.9
Gauldie, J.10
Sethi, T.11
-
28
-
-
84860524460
-
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II
-
Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 2012;7:e35144.
-
(2012)
PLoS One
, vol.7
-
-
Ma, F.1
Li, Y.2
Jia, L.3
Han, Y.4
Cheng, J.5
Li, H.6
Qi, Y.7
Du, J.8
-
29
-
-
80053073959
-
Extracellular heat shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via TLR2
-
Mathur S, Walley KR, Wang Y, Indrambarya T, Boyd JH. Extracellular heat shock protein 70 induces cardiomyocyte inflammation and contractile dysfunction via TLR2. Circulation Journal. 2011;75:2445-2452.
-
(2011)
Circulation Journal
, vol.75
, pp. 2445-2452
-
-
Mathur, S.1
Walley, K.R.2
Wang, Y.3
Indrambarya, T.4
Boyd, J.H.5
-
30
-
-
70349485623
-
aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6
-
Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T, Ishiguro-Imagawa Y, Nakaigawa N, Ohno S, Kubota Y, Uemura H. aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proceedings of the National Academy of Science of the United States of America. 2009;106:16369-16374.
-
(2009)
Proceedings of the National Academy of Science of the United States of America
, vol.106
, pp. 16369-16374
-
-
Ishiguro, H.1
Akimoto, K.2
Nagashima, Y.3
Kojima, Y.4
Sasaki, T.5
Ishiguro-Imagawa, Y.6
Nakaigawa, N.7
Ohno, S.8
Kubota, Y.9
Uemura, H.10
|